BIIB NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Biogen Inc · Healthcare · Drug Manufacturers - General

Open interactive chart View report data
Latest close 202.9 USD
0.4% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 6.3% above the Trend Line and sits at 81.9% of its 52-week range. The latest completed week returned 0.4%, after a -6.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is bearish with 44/100 conviction, while the latest news-sentiment score is 57/100.

Setup score 61 out of 100
Latest Close 202.9 USD 31 Jul 2026
1W Return 0.4% latest completed week
4W Return -6.1% short-term follow-through
12W Return 4.9% quarterly tape
Trend Breadth 90.4% 47 of 52 weeks active
Volume Ratio 1.2x vs 13-week average
What is working
  • The trend backdrop is active with a 47-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • No major top-level risk cluster is currently dominant.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.4% Latest completed week; four-week move -6.1%. Indicator stack 95/57 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bearish 44/100 conviction; expected move 1.2%. News sentiment 57/100 51 relevant articles in the latest sentiment read. Event risk 30 Jul Latest stored earnings date was 30 Jul 2026.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 6.3% above the Trend Line and sits at 81.9% of its 52-week range. The latest completed week returned 0.4%, after a -6.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.2x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9012-week average 0.71

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership9/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.90Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -6.1% over four weeks, 4.9% over 12 weeks, and 53.8% over one year. The current trend has remained active for 47 consecutive weeks.

Performance by holding period

1W0.4%
4W-6.1%
12W4.9%
26W12.8%
52W53.8%
Active trend streak47 weeks
Active weeks in one year47
Trend breadth90.4%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.58Latest activity-pressure read.
Pressure change-38.7%Four-week change in activity pressure.
Leadership6.02Latest relative-leadership reading.
RS change-43.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 97% Model confidence 93%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength66/100Blend of value, momentum, and quality. Underlying universe rank 35; rank 1 is best.
Value32/100Relative valuation strength. Underlying universe rank 69; rank 1 is best.
Quality75/100Profitability and accounting quality. Underlying universe rank 26; rank 1 is best.
Momentum88/100Medium-term price momentum. Underlying universe rank 13; rank 1 is best.
Growth3/100Revenue and earnings growth. Underlying universe rank 98; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework50/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
21.8x
Price divided by trailing earnings.
Price / sales
3.0x
Market value relative to trailing revenue.
EV / EBITDA
12.2x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
8.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
69.8%
Gross profit retained from each unit of revenue.
Operating margin
18.4%
Operating profit retained from revenue.
Free-cash-flow margin
27.9%
Free cash flow generated from revenue.
Return on invested capital
7.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
0.4%
Latest one-year revenue growth.
EPS growth
-7.2%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-4.1%
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBearish

BIIB shows bearish options pressure with a 44/100 conviction score, put-call volume ratio of 1.50, expected move of 1.2%, and Sharemaestro trend signal active.

Conviction44/100
Expected move1.2%
Put/call volume1.50
Pressure-18
Speculation43
Volatility47
Trend agreement85
Open options detail
Insider activity12 / 5

12 acquisitions and 5 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment57/100

Weighted news tone is neutral across 51 relevant articles.

24 positive · 23 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings30 JulLatest stored earnings date was 30 Jul 2026.
Options expected move1.2%Nearest-chain priced movement where available.
52-week drawdown-7.6%Distance below the 52-week high.
13-week volatility3.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+11.8%Week of 6 Feb.
Worst week-7.9%Week of 10 Jul.
Latest week+0.4%Week of 31 Jul.

Shape of recent returns

Strong gains2
Modest gains11
Flat weeks0
Modest losses12
Sharp losses1
Recent vol3.8%13-week weekly-return volatility.
Base vol4.8%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew3.9% / -3.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape66/100

Trend, activity pressure, participation, and risk combine to a 66/100 tape read.

 Indicator analysis80/100

Latest 12-week confirmation: trend 12/12, activity pressure 9/12, relative leadership 9/12.

Activity pressure 0.90; No reversal markers Factors64/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 43 SVQF50/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 361.5 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options52/100

BIIB shows bearish options pressure with a 44/100 conviction score, put-call volume ratio of 1.50, expected move of 1.2%, and Sharemaestro trend signal active.

Bearish · Put-side pressure · Expected move 1.2% Sentiment57/100

Weighted news tone is neutral across 51 relevant articles.

Biogen Inc. stock underperforms Friday when compared to competitors Insiders12 / 5

12 acquisitions and 5 disposals in the latest 180-day insider tape.

 Earnings30 Jul

Latest stored earnings date was 30 Jul 2026.

 Research flow2 items

1 recent research articles and 1 Market Watch posts are available.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 2026202.9 USD0.4%190.9 USD187.8 USD0.586.027.0MOn
24 Jul 2026202.2 USD-1.8%190.0 USD188.3 USD0.756.614.1MOn
17 Jul 2026206.0 USD3.4%189.2 USD188.7 USD1.087.3511.3MOn
10 Jul 2026199.2 USD-7.9%188.2 USD189.1 USD0.93-0.037.1MOn
3 Jul 2026216.1 USD0.0%187.3 USD189.6 USD0.9510.704.7MOn
26 Jun 2026216.0 USD9.9%186.2 USD190.0 USD0.7612.107.8MOn
19 Jun 2026196.6 USD-1.7%185.0 USD190.5 USD0.43-2.064.7MOn
12 Jun 2026200.1 USD2.4%184.3 USD191.0 USD0.272.504.9MOn
5 Jun 2026195.3 USD-0.3%183.2 USD191.6 USD0.052.614.4MOn
29 May 2026196.0 USD1.2%181.9 USD192.4 USD-0.07-1.514.3MOn
22 May 2026193.8 USD0.4%180.5 USD193.0 USD-0.140.295.4MOn
15 May 2026192.9 USD-0.3%179.1 USD193.7 USD-0.191.248.3MOn
8 May 2026193.4 USD3.4%177.4 USD194.5 USD-0.411.403.5MOn
1 May 2026187.1 USD1.5%175.8 USD195.2 USD-0.583.667.0MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.